Injectable Hybrid SMART spheroids to enhance stem cell therapy for CNS injuries
Project Number5R01NS130836-02
Former Number1R01NS130836-01
Contact PI/Project LeaderLEE, KIBUM
Awardee OrganizationRUTGERS, THE STATE UNIV OF N.J.
Description
Abstract Text
PROJECT SUMMARY
Current stem cell-based treatments for central nervous system (CNS) injuries such as spinal cord injury (SCI),
are severely hampered by poor stem cell survival rates, inefficient integration, loss of neural plasticity, and
uncontrollable differentiation of implanted cells, all of which are caused by the highly inhibitory and inflammatory
microenvironment at disease or injury sites. Specifically, gliosis at the injury site causes the secretion of inhibitory
factors leading to poor axon regeneration and sprouting of surviving neuronal populations, resulting in the
intrinsic limitations of the CNS to regenerate after the initial injury. Therefore, there is an urgent need for effective
strategies to generate a robust population of functional neurons derived from patient-derived stem cells and re-
establish the damaged neural circuitry. To this end, we propose to integrate several fields of research, including
nanotechnology, biomaterials, neuroscience, and stem cell biology, to develop a novel nanoscaffold-based stem
cell assembly platform that allows for the generation of favorable microenvironments during stem cell
implantation and the control of stem cell fate in vivo for potential clinical applications.
To address the fundamental impediment of regeneration associated with CNS injuries and diseases, we
propose to develop injectable 3D-Hybrid SMART neuro-spheroids for enhanced stem cell therapy and effective
treatment of SCI in vivo. The 3D-Hybrid SMART neuro-spheroids are assembled from biodegradable scaffold
nanomaterials enriched with natural neural ECM to promote neural stem cell (NSC) survival and differentiation.
The SMART neuro-spheroids also permit the loading of a bioactive molecule (i.e., Notch inhibitor), resulting in
the synergy between suppressing neuroinhibitory signaling and promoting neural stem cell (NSC) survival and
differentiation. This novel technology platform will be further integrated into two clinically advanced models: i) an
inflammatory CNS organoid model incorporated with microglia, and ii) a spinal cord injury animal model. This
multidisciplinary study will provide a next-generation platform for research and cell therapy in neuro-regenerative
medicine from the perspective of developing a new 3D spheroid assembly method for enhanced stem cell
survival and suppression of inhibitory environment after CNS injuries.
We propose to verify our central hypothesis and achieve our objectives by addressing the following specific
aims: AIM #1 – Develop bioactive and biodegradable-nanoscaffold-based injectable 3D-Hybrid SMART
spheroids; AIM #2 – Investigate deep drug (Notch-i) delivery in SMART spheroids and study neuronal
differentiation of stem cells and axonal growth under neuroinhibitory and immune microenvironments
in vitro; AIM #3 – Determine the therapeutic effects of 3D-Hybrid SMART spheroids on the modulation of
neuroinhibitory microenvironments and the enhancement of SCI functional recovery in vivo. Collectively,
we anticipate that our proposed studies will provide an innovative, highly effective, and robust method for
developing therapeutic interventions for neurological disorders.
Public Health Relevance Statement
PROJECT NARRATIVE
Our proposed studies are relevant to public health, as developing an injectable, biocompatible, and
biodegradable method to form therapeutic 3D spheroids to promote stem cell therapy will facilitate CNS repair
and modulate neuroinhibitory microenvironments after CNS injury. Therefore, the proposed research is relevant
to the part of NIH’s mission that relates to treating human illness and disability by investigating how innovative
technology can safely translate to clinics.
NIH Spending Category
No NIH Spending Category available.
Project Terms
3-DimensionalAddressAnimal ModelAxonBiocompatible MaterialsBiological ProcessCell Differentiation processCell TherapyCellsCentral Nervous SystemCentral Nervous System DiseasesCharacteristicsCicatrixClinicClinicalComplexCuesDataDevelopmentDifferentiation and GrowthDiseaseDrug Delivery SystemsEnvironmentExtracellular MatrixFunctional disorderGenerationsGliosisGoalsGrowthHumanHybridsImpairmentImplantIn VitroInflammationInflammatoryInjectableInjuryInvestigationLamininMedicineMethodsMicrogliaMissionModelingNanotechnologyNatural regenerationNerve RegenerationNervous System DisorderNeuritesNeurologic DeficitNeuronal DifferentiationNeuronal PlasticityNeuronsNeurosciencesNeurosphereOrganoidsPatientsPopulationProliferatingPropertyPublic HealthRecovery of FunctionResearchSignal TransductionSiteSpinal cord injuryStem cell transplantSurvival RateSystemTechniquesTherapeuticTherapeutic EffectTherapeutic InterventionTissuesTranslatingTreatment outcomeUnited States National Institutes of Healthaxon growthaxon regenerationaxonal sproutingbiodegradable scaffoldbiomaterial compatibilitycell assemblycentral nervous system injuryclinical applicationcontrolled releasedifferentiation in vitrodisabilityeffective therapyimplantationimprovedin vivoinflammatory modulationinhibitorinnovationinnovative technologiesmultidisciplinarynanonanomaterialsnerve stem cellneuralneural circuitneurogenesisneuronal growthneuronal survivalnew technologynext generationnotch proteinnovelpatient - derived stem cellspermissivenessregeneration potentialrepairedscaffoldspatiotemporalspheroidsstem cell biologystem cell differentiationstem cell fatestem cell growthstem cell survivalstem cell therapystem cellssuccesssynergismtechnology platformthree dimensional cell culturetooltumor-immune system interactions
National Institute of Neurological Disorders and Stroke
CFDA Code
853
DUNS Number
001912864
UEI
M1LVPE5GLSD9
Project Start Date
15-June-2023
Project End Date
31-May-2028
Budget Start Date
01-June-2024
Budget End Date
31-May-2025
Project Funding Information for 2024
Total Funding
$373,413
Direct Costs
$238,784
Indirect Costs
$134,629
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Neurological Disorders and Stroke
$373,413
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01NS130836-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01NS130836-02
Patents
No Patents information available for 5R01NS130836-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01NS130836-02
Clinical Studies
No Clinical Studies information available for 5R01NS130836-02
News and More
Related News Releases
No news release information available for 5R01NS130836-02
History
No Historical information available for 5R01NS130836-02
Similar Projects
No Similar Projects information available for 5R01NS130836-02